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ABSTRACT 
 
Development and validation of the Short Version of Diabetes Obstacles Questionnaire 
(DOQ) to assess obstacles in managing Type 2 diabetes among patients of Estonia 
 
The aim of this study was to develop the Short Version of Diabetes Obstacles Questionnaire 
(SDOQ), a less time consuming measure, to assess the obstacles in managing type 2 diabetes 
among patients in Estonia. The SDOQ is based on the 78-item Diabetes Obstacles 
Questionnaire previously validated in Estonia (DOQ; Kongi, 2001; Hearnshaw, Dale, Sturt, 
Vermeire, and Van Royen, 2007). 267 respondents participated in the study (137 in Estonia, 
130 in Slovenia). General practitioners invited 5 consecutive diabetic patients to participate in 
the study, who completed the DOQ and the Problem Areas in Diabetes Score (PAID; Welch, 
Jacobson, and Polonsky, 1997). Demographic and medical data was collected in addition. 
Statistical analyses for estimating dimensionality and homogeneity of the measure, and 
correlations with the PAID and glycemic control were performed in SPSS version 15.0. 
Further analysis of dimensionality of the SDOQ subscales, and measurement invariance cross 
culturally was estimated on data of Estonian and Slovenian respondents with single- and 
multi-group Confirmatory Factor Analysis (CFA) with program Lisrel 8.80 (Jöerskog & 
Sörbrom, 2006). CFA resulted in the 40-item measure with 6 subscales. The subscales 
demonstrated acceptable internal consistency (Cronbach’s alpha .67-.86 in Estonia, and .66-
.85 in Slovenia) and CFA models showed acceptable fit levels. Most subscales were 
significantly correlated with the PAID (Pearson r from 0.15 to 0.46 in Estonia, and .07-.45). 
Acceptable measurement invariance was only partly confirmed. Therefore, future research is 
needed to confirm the cross-cultural validity of the SDOQ. In conclusion, the SDOQ is a valid 
instrument to measure obstacles to treatment adherence and diabetes self-management living 
in Estonia.  
 
Keywords: type 2 diabetes, management, confirmatory factor analysis, measurement 
invariance 
Running head: Development of the SDOQ in Estonia 
 
3 
Running head: Development of the SDOQ in Estonia 
  
KOKKUVÕTE 
 
Diabeediga Kohanemise Takistuste Küsimustiku Lühiversiooni väljatöötamine ja 
valideerimine teist tüüpi diabeediga patsientidel Eestis. 
 
Antud uurimuse eesmärk oli töötada välja ja valideerida kasutaja-sõbralik Diabeediga 
Kohanemise Takistuste Küsimustiku Lühiversioon Eesti andmetel, et hinnata diabeediga 
toimetulemisel sagely esinevaid takistusi. Küsimustik on väljatöötatud baseerudes eelnevalt 
Eestis valideeritud 78-väitelise Diabeediga Kohanemise Takistuste Küsimustikul (DOQ; 
Kongi, 2001; Hearnshaw, Dale, Sturt, Vermeire, and Van Royen, 2007). Uuringus osales 
kokku 267 vastajat (137 Eestis, 130 Sloveenias). Perearstid kutsusid 5 järjestikust diabeediga 
patsienti uuringusse, kes täitsid Diabeediga Kohanemise Küsimustiku ja küsimustiku 
diabeediga seotud probleemide kohta. Samuti koguti demograafilisi ja meditsiinilisi andmeid. 
Hindamaks küsimustiku dimensionaalsust, sisemist reliaablust ja seoseid veresuhkru taseme 
ning diabeediga seotud probleemide küsimustikuga (the Problem Areas in Diabetes Score; 
Welch, Jacobson, and Polonsky, 1997) viidi läbi statistiline analüüs programmis SPSS 15.0. 
Kinnitava faktoranalüüsiga leiti andmetele kinnituvad faktormudelid, mille sobituvust 
mõõdeti ka Sloveenia andmetel. Analüüsiks kasutati programmi Lisrel 8.80 (Jöerskog & 
Sörbrom, 2006). Kinnitava faktoranalüüsi tulemusel loodi mõõdik 40 väitega, mis jaotusid 6 
alaskaala vahel. Alaskaalade sisemine reliaablus oli aktsepteeritav (Cronbach’s alpha .67-.86 
Eestis, ja .66-.85 Sloveenias) ja mudelite sobitusandmetele oli väga hea. Enamik alaskaaladest 
olid statistiliselt oluliselt korreleeritud PAID-ga (Pearson r vahemikus 0.15-0.46 Eestis ja .07-
.45 Sloveenias). Küsimustiku mõõtmise invariantsus leidis vaid osaliselt kinnitust. Seega, 
vajab küsimustiku kultuuride-vahelise kasutuse hindamine edasist uurimist. Kokkuvõttes on 
Diabeediga Kohanemise Takistuste Küsimustiku Lühiversioon valiidne mõõtmisvahend, et 
hinnata diabeediga patsientide toimetulekut ja takistusi Eestis.  
 
 
Keywords: II tüüpi diabeet, küsimustik, kinnitav faktoranalüüs, mõõtmise invariantsus 
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INTRODUCTION 
 
 
Type 2 diabetes mellitus has become one of the most common chronic diseases 
worldwide (Shaw, Sicree & Zimmet, 2010) and is considered to account for 90-95% of all 
diabetes cases. According to the International Diabetes Federation Annual Report 2011, it is 
estimated that about 366 million people above 20 years of age are diagnosed with diabetes 
and the rise in the numbers of people with diabetes was estimated to reach 554 million by 
2030. Increasingly higher rates of people who suffer from diabetes are a consequence of the 
population aging and urbanization, even if the prevalence of obesity remains the same (Wild, 
Roglic, Green, Sicree & King, 2004).  
 
Type 2 diabetes mellitus 
Type 2 diabetes mellitus develops gradually and is diagnosed mostly in later 
adulthood. Diabetes mellitus leads to persistently elevated blood glucose levels due to 
increasing deficiency of insulin production or insulin resistance of body cells (Kuzuya, 
Nakagawa, Satoh et al., 2002). Normal glucose levels in the blood range from 3.6 to 5.8 
mmol/L. Prolonged elevated blood glycose levels, referred to as hyperglycemia, damage 
various organs and tissues that may lead to death (Kuzuya et al., 2002). Glycated (HbAc1) 
haemoglobin has been a widely accepted indicator of glycemic control while promising data 
from the series of United Kingdom Prospective Diabetes Studies have shown reduction of the 
risk of some diabetes related complications and mortality with intensive treatment of 
hyperglycaemia (Stratton et al., 2000; Turtner et al., 1998, UK Prospective Diabetes Study 
Group, 1998). Based on the International Diabetes Federation webpage, cardiovascular 
diseases account for 50% of causes of death in people with diabetes. Damaging effects of 
diabetes on blood vessels can also cause kidney failure, neuropathy as retinal failure or 
blindness due to nerve damage, and loss of sensitivity in limbs that may lead to ulceration and 
amputation of the toes, feet and lower limbs (International Diabetes Federation Annual Report 
2011).  
Diabetes has a negative impact not only on the physical health, but also sets a heavy 
psychological burden on the person due to the continuously present risk of serious health 
complications, and demands significant changes in the habits and every day life routine of a 
person. This can be a source of emotional stress (Rubin & Peyrot, 2001). Fischer and 
colleagues (2007) used the CESD (Center for Epidemiological Studies Depression Scale) and 
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CIDI (Composite International Diagnostic Interview) to evaluate the relationship between 
diabetes and depression and they reported that 22% of diabetic patients had scores above a 
cut-off point on the CESD of which 9.9% had clinical depression. Diabetic patients 
experiencing emotional stress (CESD >15) had higher HbA1c, consumed kilocalories, 
consumed calories from saturated fat, and lower physical activity. Anderson and colleagues 
(2001) have also reported that diabetes raises the risk of burnout and consequently may lead 
to depression. Depression itself and its pharmacotherapy may decrease (tricyclic 
antidepressants, Aronne & Segal, 2003; Lustman, Griffith, Clouse, et al., 1997) or increase 
insulin sensitivity (selective serotonin reuptake inhibitors, Rubin, Ma, Marrero et al., 2008; 
Maheux, Ducros, Borque, Garon, Chiasson, 1997). Thus, diabetes management is a complex 
process, which needs interventions planned by considering various aspects (Cox, Stephenson, 
Britten, Dundar, 2004; Gentili, Maldonato, Grieco, Santini, 2001). 
 
Adherence to treatment of type 2 diabetes 
Diabetes management involves administrating medication or insulin, monitoring and 
maintaining normal blood glucose levels by proper diet, physical exercise and other 
behaviors, e.g. avoiding smoking (Saudek, & Margolis, 2009). Therefore, management of 
diabetes does not demand from health-care professionals merely prescribing medicine or 
conducting other medical treatment procedures, but rather expects active partnership between 
health-care personnel and diabetic patient (Vermeire & Hearnshaw, Van Royen, Denekens 
2001; Hearnshaw & Lindenmeyer, 2005).  
Diabetes treatment often requires regular pharmacotherapy and adherence to 
prescribed medication regime can be undermined by unreported side effects and low 
confidence in treatment (Grant, Devita, Singer & Meigs, 2003). Moreover, constant need to 
adapt one’s daily life to diabetes treatment may be considerable obstacles to the successful 
adherence to treatment and management of the disease (Hearnshaw & Lindenmeyer, 2005; 
Vermeire et al., 2006). Patients need to be provided with information and involved actively in 
discussion about the disease, treatment and it’s alternatives, and also advice and mentoring to 
achieve effective self-management skills, e.g. continuous self-monitoring of blood sugar 
levels (up to 4 times per day), strict diet, additionally physical activity (Vermeire et al., 2001; 
Hearnshaw & Lindenmeyer, 2005). A systematic review of various diabetes interventions’ 
effectiveness by Renders and colleagues (2001) suggested a positive effect on treatment 
outcome and process when multiple professional interventions were incorporated into 
diabetes care, e.g. patient education, feedback, and nurse consultations.  
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In addition, monitoring patient’s social support levels and involving family members 
in diabetes interventions are recommended, since research has demonstrated that patients self-
care behaviors are either discouraged or supported by family or friends (Mayberry & Osborn, 
2012; Al-Qazaz, Hassali, Shafie, Sulaiman & Sundram, 2010).  
Besides direct communication in the primary care or hospital settings, providing 
patients with reliable printed materials or online sources, web-based diabetes management 
programs or communication platforms has demonstrated to improve glycemic control, 
improve various parts of care processes and reduce financial cost of diabetes treatment (Bu, 
Walker, Adler-Milstein et al., 2007; Ralston, Hirsch, Hoath, Mullen, Cheadle, Goldberg, 
2009).  
 
Development and validation of Diabetes Obstacles Questionnaire 
Valid measures are essential for not only estimating the outcome (lower glycemic 
levels), but also the process of diabetes, e.g. communication with health-care, diabetes related 
emotional stress (Welch, Jacobson & Polonsky, 1997), and persons’ own reports of 
difficulties with managing diabetes (Hearnshaw & Lindenmeyer, 2005) in order to improve 
diabetes interventions.  
Based on literature (Rubin & Peyrot, 2001; Piett, Schillinger, Potter, Heisler, 2003; 
Vermeire et al., 2001), qualitative studies of focus group discussions with diabetic patients in 
UK and Flandria (Vermeire, Van Royen, Coenen, Wens, Denekens, 2003), and consecutively 
in 6 European countries (Vermeire, Hearnshaw, Rätsep et al., 2007) Hearnshaw and 
colleagues (2007) developed a 78-item Diabetes Obstacles Questionnaire (DOQ) measuring 
patients’ beliefs and opinions on the following areas: medication adherence, information and 
knowledge of diabetes, relationship with medical personnel, lifestyle changes and daily self-
monitoring, burden of diabetes, and social support. This was developed on 176 diabetic 
patients in United Kingdom along with The Problem Areas in Diabetes Scale (PAID; Welch 
et al., 1997), and Diabetes-Dependent Quality of Life (ADDQoL; Bradley, Tood, Gorton, 
Symonds, Martin, Plowright, 1999) to test construct validity. PAID and ADDQoL are both 
widely used measures to estimate diabetes related emotional stress and quality of life. The 
DOQ 78-items were divided into 8 subscales and all subscales demonstrated significant 
correlations with the PAID scale, while only some subscales were significantly correlated 
with the ADDQoL. Moreover, the DOQ subscales related to HbA1c levels, were significantly 
related to patients’ objective glucose levels. It also demonstrated good internal consistency on 
all 8 subscales (Cronbach’s alpha >.75; Hearnshaw et al., 2007). 
8 
Running head: Development of the SDOQ in Estonia 
  
Validation of the Diabetes Obstacles Questionnaire is currently in process in six 
other countries of Europe (France, Belgium, Slovenia, Serbia, Turkey, and Estonia). The 
DOQ has demonstrated sufficient reliability (Cronbach’s alpha > .76) on Belgium data 
(Vanderkerckhove, Vermeire, Weeren & Van Royen, 2009), however correlations between 
the PAID and the 8 subscales of the DOQ were only partly statistically significant and weaker 
(between .03 and .48) compared to UK (Hearnshaw et al., 2007). Kongi (2011) has reported 
the reliability (Cronbach alpha’s from .67 to .90) and validity (correlations with PAID 
between .21 and .55) of the DOQ for Estonian data. In addition, dimensionality of the DOQ 
subscales in Estonia was analyzed by use of Exploratory and Confirmatory Factor Analysis, 
and elimination of 16 items was recommended (Kongi, 2011). 
 
Present study 
The Diabetes Obstacles Questionnaire development was based on intensive analysis of 
literature and qualitative studies. It covers numerous important aspects in diabetes care and 
management (Vandekerckhove et al., 2009). Kongi (2011) has suggested that the DOQ has 
acceptable reliability and validity, but changes made in the original the DOQ measure by 
eliminating items could result in a more cohesive measure. Therefore, the goal of the present 
study was to develop a shorter version of the Diabetes Obstacles Questionnaire. A measure 
with fewer items would be less time consuming and easier to administer for practitioners for 
identifying and adapting to patients’ needs, and also for research purposes to estimate the 
process and outcome of interventions designed to enhance self-management in diabetes in 
Estonia. 
The item content, discriminability, and inter-correlations were more rigorously 
analyzed to achieve the DOQ measure specifically tailored for Estonian data. Moreover, 
previous research has suggested that concerns and management of diabetes may be influenced 
by ethnical and cultural differences (Caballero, 2007), the final goal of the present study was 
to examine the DOQ cross-cultural applicability by analyzing measurement invariance of the 
Estonian Version of the DOQ on data collected in Slovenia. Multi-group Confirmatory Factor 
Analysis with LISREL 8.80 (Jöerskog, and Söbrom, 2006) was applied to analyze 
measurement invariance (Milfont & Fischer, 2010) 
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METHOD 
 
Instrument Development 
 
The Diabetes Obstacles Questionnaire    
The Diabetes Obstacles Questionnaire (DOQ) was developed in UK by Hearnshaw et al. 
(2007). The questionnaire initially comprised 78 items assigned to 8 different subscales: 
Medication (10 items), Self-Monitoring (5 items), Knowledge and Beliefs (10 items), 
Diagnosis (6 items), Relationships with Health-Care Professionals (18 items), Lifestyle 
Changes (13 items), Coping (8 items) and Advice and Support (8 items). The items were rated 
on a 5-point scale from 1 to 5 (strongly disagree, disagree, neutral, agree, strongly agree). 
 
The Problem Areas in Diabetes Scale  
Also included in the current survey was the Problem Areas in Diabetes Scale (PAID; 
Polonsky et al., 1995), a 20-item questionnaire that is widely used as a measure of diabetes-
related psychosocial distress. Each item is rated on a 6-point Likert scale, reflecting the 
degree to which the item is perceived as currently problematic: 0 - “not a problem” and 4 - “a 
serious problem”.  A total scale score ranging from 0 to 100, which is hypothesized to reflect 
the level of diabetes-related emotional distress, is then computed by summing the total item 
responses, with a higher total scale score indicating greater emotional distress. 
 
Translation procedure 
The questionnaires were conducted simultaneously in 6 different countries - Estonia, 
Slovenia, Serbia, Turkey, France and Belgium. However, in this thesis only the data of 
Estonia and Slovenia is included. The studies were approved by the Ethics Committees and 
the questionnaires were coded for anonymity. In Estonia the study coordinator was Anneli 
Rätsep, in Slovenia Davorina Petek.  
The translations into native languages and the back translation into English were 
performed in all 6 countries. The Estonian questionnaire was also piloted in a sample of five 
people with type 2 diabetes in order to identify any potential problems of comprehension. 
However, no changes were required.  
 
Participants and procedures 
In this study participated 267 individuals with diagnosed type 2 diabetes mellitus  (61 
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males of 137 participants in Estonia and 74 males of 130 participants in Slovenia). General 
practitioners were randomly selected from the list of the National Associations of GPs and 
invited by e-mail to participate in the study. They invited five consecutive diabetes patients to 
participate in the study. The inclusion criteria for the patients were: outpatient status, 
diagnosis of type 2 diabetes mellitus, any age and gender. Participants were given a study 
pack, which included an information leaflet, a questionnaire pack and pre-paid, self-addressed 
envelopes. Participants were provided the opportunity to complete the packet in the clinic or 
take it home for completion. Altogether in two countries 267 participants returned the study 
packs. 
The means or frequencies of gender, age, body mass index (BMI), diabetes duration, 
and most recent levels of glycated hemoglobin are reported in Table 1. T-test indicated the 
statistically significant differences between countries in age, BMI, and HbA1c. Cohen’s d’s 
and effect-size correlations were following: age, (d=.37; r=.18), BMI (d=.28; r=.14), HbA1c 
(d=-.31; r=-.15). However, it is currently not known if these differences between countries 
exist in general or only in the sample of the current study.  
The age of participants ranged from 34 to 89 years, with the mean age being 66.8 
years for Estonian participants and 63 years for Slovenian participants. Participants’ body 
mass index varied between 18.7 and 50.2 and diabetes duration ranged from 0 to 26 years. 
HbA1c levels ranged from 5.20 to 14, when an HbA1c level above 8.00 is considered 
hazardous.  
 
Table 1. Demographic information of Estonia and Slovenia. 
Table 1  Gender Age BMI DD HbA1c 
Estonia Mean 
(SD) 
61 Male  
76 Female  
66.8 (9.8) 32.5 (6.0) 8.61 (5.1) 7.1 (1.2) 
 N 137 137 130 132 131 
Slovenia Mean 
(SD) 
76 Male 
 54 Female 
63.0 (10.9) 30.9 (5.0) 9.7 (6.6) 7.5 (1.4) 
 N 130 130 127 126 125 
Total Mean 
(SD) 
135 Male 
132 Female 
65 (10.17) 32 (5.56) 9.13 (5.85) 7.00 
(1.34) 
 N 267 267 257 258 256 
 
Note.  DD - duration of diabetes; N - sample size; SD - standard deviation (in the brackets) 
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Statistical Analysis 
All data from questionnaires completed by patients and collected by the practice staff 
was placed in a Microsoft Excel spreadsheet, coded and then transferred to SPSS format. 
Statistical analyses were conducted using SPSS version 15.0. Internal consistency was 
calculated for all scales separately for both Estonian and Slovenian data. Next, a 
Confirmatory Factor Analysis with program LISREL 8.80 (Jöerskog, and Söbrom, 2006) was 
performed on each scale separately with a slightly different number of participants (due to 
exclusion of all individuals with missing data while performing the CFA). Alternative 
hypothetical models based on the unpublished thesis of Kongi (2011) and on the results of the 
Exploratory Factor Analysis (principal axis method, varimax) were performed first on 
Estonian data. The estimation method used was unweighted least squares (ULS), as there was 
non-normality in the data.  
One of the goals of this research was to decrease the number of items in order to make 
the questionnaire more easy to use for practitioner. Therefore, based on goodness-of-fit 
indices, models with the highest fit indices and with least number of items were included in 
the final measure. A chi-square goodness-of-fit test and information about modification 
indices were evaluated to make the changes in the model to find a better fit of the data to the 
model. Also, additional goodness-of-fit indices used to evaluate the structural models 
included: root mean square error of approximation (RMSEA), standardized root mean square 
residual (SRMR), comparative fit index (CFI, values between .00 to 1.00), and goodness of fit 
index (GFI, values range from .00 - 1.00). The values of the RMSEA of .05 or less indicate a 
close fit, and values between .05 and .08 the modest fit. SRMR ranges from .00 to 1.00, and a 
value of less than .08 indicates a good fit. GFI values above .95 indicate a good fit. A value of 
>.95 is considered as a criterion for adequate fit in CFI, a measure of complete covariation in 
the data (Hu, and Bentler, 1999).  
After conducting the CFA on the Estonian data, the measurement invariance across 
two countries was tested by performing the multi-group CFA on Estonian and Slovenian data. 
Measurement invariance (or equivalence) can be evaluated by increasing restrictions set for 
models (decreasing numbers of parameters). Four of the models are in hierarchical order. 
Configural invariance (form invariance) model constrains the factorial structure to be the 
same across groups, indicating that participants from different groups conceptualize the 
constructs in the same way. Metric invariance model constrains all factor loadings to be the 
same across groups, testing if different groups respond to the items in the same way (needed 
to estimate weak measurement invariance). Scalar, or intercept, invariance model constrains 
12 
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the intercepts of items to be the same across group to test if participants who have the same 
score on latent construct obtain the same score on the observed variable regardless of their 
group belonging. Error variance model is applied to test if the error variances are the same 
across groups (Milfont & Fischer, 2010). These increasingly constrained models are applied 
to evaluate the fit of the data to the model in multi-group CFA (Cheung & Rensvold, 2002). 
Weak measurement invariance is demonstrated by metric invariance. Strong measurement 
invariance requires fit on metric and scalar models. Strict measurement invariance is 
achieved, when all 3 levels demonstrate good fit (Dimitrov, 2012). 
13 
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RESULTS 
 
The reliability and the validity of the new shorter scale were estimated by measuring 
internal consistency, latent factor structure, and correlations with the PAID and the HbAc1. In 
addition, the measurement invariance model fit indices are reported to estimate potential 
applicability of Short Version of DOQ across cultures. 
 
Homogeneity and dimensionality of the Short Version of DOQ 
The results of internal consistency of the new shorter scale are reported in comparison 
with the original scale in Table 2. The reliability of the new scales is mostly acceptable: all 
scales have Cronbach’s alphas above .70, except Medication scale with 7 items (Cronbach’s 
Alpha of .66) on the data of Slovenia and Self-Monitoring scale with 4 items (Cronbach’s 
Alpha of .68) on the data of Estonia. In the Short Version of DOQ, two new subscales were 
developed through merging the subscales 3 and 4, also 6 and 7. 
 
Table 2. Internal Consistency of all scales for Estonia and Slovenia (Cronbach’s alpha). 
DOQ Subscales N1 EST SLO N2 EST SLO 
1. Medication 10 .76 .73 7 .70 .66 
2. Self-Monitoring 5 .74 .79 4 .68 .71 
3. Knowledge and Information 10 .79 .88 
8 .79 .85 
4. Diagnosis 6 .67 .79 
5. Relationships with Health-Care 18 .90 .92 7 .84 .83 
6. Lifestyle  13 .79 .83 
9 .86 .85 
7. Coping 8 .81 .76 
8. Support 8 .79 .82 5 .70 .75 
 
Note. N1 - number of items in original the DOQ, N2 - number of items in the Short Version of DOQ  
 
A Confirmatory Factor Analysis was carried out on Estonian data separately on each 
subscale. The number of individuals varied from 101 to 128 due to exclusion of all 
individuals with missing values. At first, single factor models including all items were carried 
out in order to test the approach applied in the studies of Hearnshaw et al. (2007) and 
Vandekerckhove et al. (2009), however this approach resulted in poor fit on all subscales of 
Estonian data.  
The aim of the subsequent CFA was to reach the model with the best goodness-of-fit 
indices for the data. A CFA with alternative models was carried out based on reducing the 
14 
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item content similarity and preserving items with high percentage of participants reporting to 
have had  “obstacles” with the theme of an item were excluded. The CFA resulted in a 40-
item measure with 10 latent factors and 6 subscales (see Table 3). Goodness-of-fit indices 
indicate a good or acceptable fit for all models. However, 90% confidence intervals of the 
RMSEA are above .08 for models of scales 1, 2 and 8 indicating a chance of a poor fit. 
 
Table 3. Goodness-of-fit indices for 10 latent indicators of the SDOQ (with 40 items in total, 
and 38 items of the original DOQ excluded) in Estonia. 
DOQ Subcales N Observed  
indicators 
χ² df p RMSEA SRMS CFI GFI 
 1. Subscale  7 Eliminated: 4 5 6       
Doubts with Treatment  1 2 3 11.77 12 .46 .00  
(.00-.089) 
.059 1.00 .98 
Tablet Intake Obstacles   3 7 8 9 10       
 2. Subscale  4 Eliminated: 5        
Self-Monitoring 
Difficulties 
 1 2 3 4 .79 2 .67 .00 
(.00-.15) 
.026 1.00 1.00 
 3-4. Subscale  8 Eliminated: 3 scale: 5 7 8 9 10   4 scale: 3 4 6    
Diabetes Knowledge  3: 1 2 67    
4: 1 5 
10.78 18 .90 .00  
(.00-.034) 
.038 1.00 .99 
Lack of Information   3: 2 3 4        
 5. Subscale  7 Eliminated: 1 2 3 4 5 7 11 13 14 17 18     
Treatment advice   6 8 9 10  7.17 12 .85 .00  
(.00-.052) 
.029 1.00 1.00 
Relationships with 
Health-Care 
  9 12 15 16       
 6-7. Subscale  9 Eliminated: 6 scale: 2 3 9 12 13     7 scale: 4 5 6 7 8    
Managing Diabetes   6: 1 4 5 6 7 8    
7: 1 2 3 
36.70 41 .59 .00  
(.00-.052) 
.052 1.00 .99 
Exercising Obstacles   6: 4 8 10 11       
 8. Subscale  5  Eliminated: 1 5 7     
Support  2 3 4 6 8 4.77 5 .44 .00  
(.00-.12) 
.048 1.00 .99 
Total 40          
Note. χ²- chi-square index; df- degrees of freedom; p- statistical significance for chi-square; N - Number of items 
after the CFA 
 
Excluded items included the following: 3 items of the Medication subscale (4, 5, 6), 
one item of the Self-Monitoring subscale (5), 5 items of the Knowledge and Beliefs subscale 
(5, 7, 8, 9, 10), 4 items of the Diagnosis subscale (2, 3, 4, 6), 11 items of the Relationships 
with Health-Care Professionals subscale (1, 2, 3, 4, 5, 7, 11, 13, 14, 17, 18), 5 items of the 
Lifestyle Changes subscale (2, 3, 9, 12, 13), 5 items of the Coping subscale (4, 5, 6, 7, 8) and 
3 items of the Advice and Support subscale (1, 5, 7). 
 
Multi-group CFA on the data of Estonia and Slovenia 
The measurement invariance of the models developed on the data of Estonia was 
15 
Running head: Development of the SDOQ in Estonia 
  
tested with a multi-group CFA on the data of Slovenian participants (see Table 4.) 
 
Table 4. Goodness-of-fit indices of measurement invariance on the data of Estonia and 
Slovenia. 
SDOQ Subscales Inv* χ² df p-
value 
RMSEA CFI GFI SRMR 
1. Medication  
N1= 129   N2=106 
1. 31.88 31 .42 .016 (.00-.072) 1.00 .98 .068 
2. 41.65 39 .36 .024 (.00-.07) 1.00 .97 .076 
3. 49.09 44 .27 .032 (.00-.072) .99 .97 .075 
4. 49.09 44 .27 .032 (.00-.072) .99 .97 .075 
2. Self-Monitoring  
N1=101   N2=95 
1. 2,80 4 .59 .00 (.00-.13) 1.00 1.00 .032 
2. 4.92 8 .77 .00 (.00-.082) 1.00 .99 .048 
3. 16.60 11 .12 .072 (.00-.14) .98 .99 .061 
4. 16.03 15 .38 .027 (.00-.10) 1.00 .99 .061 
3-4. Knowledge and 
Information  
N1=125   N2=123 
1. 23.22 28 .72 .00 (.00-.053) 1.00 1.00 .041 
2. 29.27 37 .81 .00 (.00-.041) 1.00 .99 .053 
3. 38.62 43 .66 .00 (.00-.051) 1.00 .99 .053 
4. 50.55 59 .77 .00 (.00-.039) 1.00 .99 .066 
5. Relationships with 
Health-Care  
N1=122   N2=118 
1. 33.12 25 .13 .052 (.00-.096) .99 .97 .11 
2. 41.14 33 .16 .046 (.00-.085) .99 .96 .11 
3. 44.58 38 .21 .038 (.00-.078) 1.00 .96 .11 
4. 52.03 44 .19 .039 (.00-.076) .99 .95 .12 
6-7. Lifestyle Changes  
N1=128   N2=125 
1. 127.66 84 .00 .066 (.041-.088) .98 .95 .12 
2. 150.21 97 .00 .068 (.045-.088) .98 .91 .13 
8. Support  
N1=125   N2=124 
1. 6.88 9 .65 .00 (.00-.031) 1.00 1.00 .030 
2. 10.19 14 .75 .00 (.00-.063) 1.00 .99 .043 
3. 18.00 18 .46 .001 (.00-.08) 1.00 .99 .049 
4. 26.73 24 .32 .030 (.00-.081) .99 .98 .077 
 
Note. χ²- chi-square index; df- degrees of freedom; p- p-value for chi-test; 1-Configural invariance; 2-Metric 
invariance; 3-Scalar invariance; 4-Error invariance; N1 - sample size of Estonia; N2 - sample size of Slovenia 
 
The majority of models demonstrated good or acceptable measurement invariance fit 
with an exception of a factor model based on the items of subscales 6 and 7 (p-value is <0.05, 
SRMR>.08; 90% confidence interval for RMSEA exceeds .08). Factor models of the 
subscales 1, 2, 5, and 8 had RMSEA values exceeding .08 in their 90% confidence intervals, 
and a factor model of the subscale 5 demonstrated poor SRMR fit index (SRMR>0.10). These 
factor models (Lifestyle Changes, Relationships with Health-Care, Self-Monitoring) indicated 
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poor fit according to some or all fit indices also on the data of Slovenia). 
 
Validity of the Short Version of DOQ 
In order to estimate the criterion validity of the DOQ scales, the correlations between 
the DOQ scales, the PAID and the glycated hemoglobin (HbA1c) are reported in Table 4. The 
correlation between the PAID and the HbA1c is reported for comparison purposes, since the 
PAID is considered to be a valid measure for estimating diabetes stress and beliefs.  
 
Table 5. Correlations between the SDOQ Scales and the PAID (Pearson’s bivariate 
correlation coefficient) for data of Estonia and Slovenia. 
SDOQ Subscales Items Estonia Slovenia 
  PAID HbA1c PAID HbA1c  
Doubts with Treatment 3 .15 .01 .07 .13 
Difficulties with Tablet Intake 5 .20** -.06 .34** .15 
Self-Monitoring Difficulties 4 .37** -.06 .37** .20* 
Knowledge about Diabetes 6 .37** -.04 .30** .16 
Lack of Information 3 .24** -.03 .21** .09 
Treatment advice 4 .31** -.06 .30** .16 
Communication with Health-Care 4 .30** -.14 .28** .06 
Managing Diabetes 9 .43** .11 .45** .22* 
Exercising Obstacles 4 .20** -.03 .16 .09 
Support 5 .46** .10 .43** .20* 
PAID 20 1 .05 1 .23** 
 
Note.  * - Correlation is significant at the .01 level (2-tailed).  
 ** - Correlation is significant at the .05 level (2-tailed). 
 
Correlations with the PAID remained between .15-.46 for the data of Estonian 
participants and .07-.45 for the data of Slovenian participants. The majority of correlations 
were statistically significant at the .05 level. However, the correlations with PAID remained 
statistically insignificant and weak with Doubts with Treatment in both countries, and 
Exercising Obstacles in Slovenia. Correlations between the glycated hemoglobin (HbA1c) 
and DOQ scales were weak and statistically insignificant in Estonia, but two statistically 
significant, though rather weak, correlations were seen between HbA1c and Managing 
Diabetes (Pearson’s r= .22), and HbA1c and Support (Pearson’s r= .20). A similar correlation 
was seen in Slovenia between PAID and HbA1c (Pearson’s r= .23). 
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DISCUSSION 
 
Development of the Short Diabetes Obstacles Questionnaire 
The main goal of the study was to develop a new shorter version of the Diabetes 
Obstacles Questionnaire (SDOQ), since the original DOQ comprises 78 items and therefore is 
rather time consuming to administer in every day practice of health-care providers.  A 
Confirmatory Factor Analysis (CFA) resulted in a 40-item measure with 10 latent indicators 
compounded of items from all 8 subscales of the original 78-item DOQ.  
The CFA was only partly guided by the division of 8 subscales suggested by previous 
research (Hearnshaw et al., 2007; Vandekerckhove et al., 2009). Due to content similarity of 
items in subscales 3 and 4 (Knowledge and Beliefs; and Diagnosis) and subscales 6 and 7 
(Lifestyle changes; and Coping), these subscales were submersed and items from both 
subscales were combined in the CFA. The aim was also to reduce the number of items similar 
in content. For example, in the original DOQ the values of Cronbach’s alpha were .90 for 
Estonia and .92 for Slovenia, indicating the high likeness of items in the subscale 5 
(Relationships with Health-Care Professionals). This was recognizable also from the content 
analysis of the measure in Estonian. All new subscales demonstrated acceptable or good 
internal consistency: Cronbach’s alphas between .68 and .86 for Estonia and from .66 to .85 
for Slovenia. Also, both in Estonia and Slovenia, less than 10% of respondents reported 
having obstacles related to the quality of basic communication (e.g. I am not being heard at 
all, my questions are not being answered). Therefore, the present study supports the notion 
reported previously (Anderson & Funnell, 2005), that problems expressed more widely in 
today’s health-care are related to discussion of treatment alternatives, advice from health-care 
providers related to self-management of diabetes, also a perceived feeling of partnership 
where both medical professionals and a patient participate in the treatment design. 
Aforementioned aspects of communication in medical care could be met by applying the new 
patient empowerment paradigm suggested by Anderson & Funnel (2010). However, it 
requires from Health-Care providers the ability to acknowledge more patients being in control 
of their daily diabetes care and medical personnel taking more action in listening and 
guidance than telling and controlling the treatment course. 
Various goodness-of-fit indices suggested the dimensionality of most subscales that 
resulted from the CFA has an acceptable fit to the data. Only one fit index (90% confidence 
interval for RMSEA) exceeded acceptable criterion for the Medication, Self-Monitoring and 
Support subscales and refers the possible risk of accepting a model not fitting the data (Type I 
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Error). However, RMSEA tends to have a positive bias (artificially high values) in case of 
small degrees of freedom and low sample size (Kenny, Kaniskan & McCoach, 2011). Thus, 
future research with a larger sample size would allow clarification of the latent factor 
structures of the SDOQ.  
 
The SDOQ measurement invariance across cultures  
The cross-cultural use of a measure is a general aim in many areas of clinical research 
and practice. However, data collected by self-reports, including beliefs and other 
psychological constructs, may yield to unreliable results due to measurement biases. Four 
levels of equivalence (functional, structural, metric and scalar) have been distinguished in 
cross-cultural literature (Fountaine, 2005). Functional invariance means that the construct 
exists in all groups studied and cannot be directly measured or declared by statistical tools. In 
case of the Diabetes Obstacles Questionnaire, the functional equivalence cross-culturally 
could be claimed to exist at least in main aspects of a construct drawing on the qualitative 
studies with focus groups in several European countries (Vermeire et al., 2007). It has been 
reported previously that differences and accentuations do exist in the quality and approach of 
health-care services for diabetic patients (Rothe, 2008; Ralston et al., 2009), availability of 
valid information about the disease and treatment (Hearnshaw et al., 2007), preferences and 
traditional customs in food consumption, access to suitable and affordable forms of physical 
activities, and in the level and type of social support (Caballero, 2007). These differences are 
also reflected in the results of the multi-group the CFA performed with the data of Estonian 
and Slovenian participants.  
The measurement equivalence varied across subscales. The goodness-of-fit indices 
suggested that factor structures, scores and levels of errors are equivalent (strict invariance) in 
both countries for the Medication subscale, and for the Knowledge and Information subscale 
(based on the original subscales 3 and 4). All goodness-of-fit indices suggested the general 
factor structure equivalence (also known as form invariance) in Slovenia and Estonia. 
However, the invariance of factor loadings, scores and error variance of Support subscale and 
for all the invariance tests of the subscale Self-Monitoring demonstrated good fit in general, 
with an exception of an RMSEA 90% confidence intervals >.08. Since the rest of the 
goodness-of-fit indices are acceptable for the subscale, then, as noted earlier, high values for 
the RMSEA could be due to positive bias of the RMSEA index with small samples. The 
Support subscale measures the perceived lack of support and discouragement of family and 
friends. So, it could be inferred that the level of social connectivity might differ in Estonia 
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and Slovenia, despite both being European countries. Similarly, the measurement invariance 
of the Relationships with the Health-Care subscale demonstrated unacceptable values of fit 
indices (RMSEA and SRMS), which could again be due to the positive bias small samples 
and low degrees of freedom. Thus, this study does not offer a clear answer if the differences 
would be present with a larger sample, although the cross-cultural differences in the objective 
quality and subjective patient’s satisfaction levels with health-care services in Europe have 
been previously reported (Hearnshaw & Lindenmeyer, 2005). 
The Lifestyle Changes subscale (combined with items from subscales 6 and 7) was the 
only subscale where measurement equivalence was not confirmed at any level (most fit 
indices indicated poor fit). The Lifestyle Changes subscale comprises items that express 
burden and difficulties experienced when making adjustments to daily routine (proper diet, 
physical activity, overall coping with diabetes in everyday life) perceived by diabetic patients. 
This confirms the results found in other studies (Garfield et al., 2003) that there exist actual 
differences in the level of burden caused by the daily struggle with diabetes. Nevertheless, it 
could be partly due to the differences in the way the problems are expressed traditionally in a 
culture. However, this seems unlikely since, if this bias existed, it would have an impact on 
all subscales of the SDOQ. The statements of this subscale could reflect the differences of 
other subscales, because the patient’s ability to cope with changing diet, fitting physical 
exercise and self-monitoring activities in their daily routine, depends both on his or her 
personal effort, social support (or discouragement), relationship with the health-care provider 
and general attitude toward diabetes, healthy diet and physical activity. Thus, this scale could 
be more sensitive to cultural differences than other subscales. 
 
The criterion validity of the SDOQ 
Criterion validity of this questionnaire was evaluated by correlations between the 
SDOQ scales and the PAID, a measure widely used by researchers and pediatricians to 
estimate emotional stress of diabetes. Hearnshaw and colleagues (2007) have previously 
reported relatively strong and significant correlations between the PAID and the original 
DOQ subscales (Pearson r between .38 and .71.) However, correlations of the current study 
for both in Estonia and in Slovenia demonstrated values at a more modest level, similarly 
seen in the Belgium study (Vandekerckhove et al., 2009). The correlations between the 
SDOQ Scales and blood sugar levels remained mostly insignificant in both Slovenia and 
Estonia, showing again more similarity with the result of Vanderkerckhove and colleagues 
(2009) study. The only significant correlations with the HbA1c were seen between two of the 
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subscales (Self-monitoring Difficulties and Managing Diabetes) in Slovenia. These two 
correlations were also the strongest in the study of Hearnshaw and colleagues (2007). These 
two subscales would be the most likely candidates for searching the direct correlations with 
physiological parameters. Self-monitoring informs the diabetic person about the current levels 
of blood sugar, and the daily burden of diabetes indicates the level of success in controlling 
the HbA1c. Although the correlations were not as strong as in the study of Hearnshaw and 
colleagues (2007), similar tendencies were seen between the subscales of the SDOQ, the 
PAID and blood sugar levels as previously reported.  
 
In the general conclusion 
The latent factor structure proposed as a result of the CFA suggests the SDOQ as a 
reliable measure for use in Estonia. This measure, which comprises both behavioral and 
attitudinal statements, possesses great potential as a tool for identifying specific obstacles of 
diabetes treatment, and after corrective changes in the treatment, the effect can be evaluated 
by this questionnaire. The factor structures of the SDOQ subscales compared on the data of 
Estonian and of Slovenian participants are mostly equivalent and the results of both countries 
are comparable with an exception of a subscale Lifestyle Changes. The future research with 
larger sample could allow exploring further the reasons causing this measurement bias. The 
SDOQ correlations with the PAID were mostly statistically significant, but remained between 
weak to moderate values. 
 
Limitations and suggestions for future research 
This study was part of a larger study conducted in 6 countries. Therefore, the future 
studies should explore the measurement invariance of both, the original 78-item DOQ and 40-
item SDOQ, in all 6 countries.  
One of the limitations of this study is the sample size below 200, which has been set as 
the minimum requirement for conducting CFA by some researchers (Barret, 2007). To reduce 
the risk of accepting false factor models due to small sample size, various goodness-of-fit 
indices were reported. Thus, future studies with a larger sample would allow further 
exploration of the factor structures of the SDOQ show adequate fit on the sample at least with 
200 respondents. Moreover, the reliability of this measure and value in predicting the course 
of the disease and treatment should be explored with a longitudinal study. 
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Appendix A 
1. Medication  Scale 
 
 
Please place one tick against each comment to indicate how much you agree or disagree with 
the statement in relation to your diabetes medicine (tablets or insulin) not other medication 
that you may be taking.  
                Strongly              Strongly 
                    Agree     Agree  Neutral  Disagree     Disagree 
1 I do not feel I am being prescribed the 
medication that is right for me                                   
     
2 I do not feel I am being prescribed the  
medication dose that is right for me                                   
 
3  I don’t know what to do about taking my medication                                  
when I am feeling unwell 
 
Even if you do not have insulin, please answer what do you think about: 
4  Using insulin makes life too complicated                                       
5  Using insulin means my diabetes is getting worse                                    
6  People treat insulin users differently                                       
 
7  I am not in a convenient place when it is time to                                  
     take my medication    
8  I often forget to take my medication                                    
9  My medication causes unwanted side effects                                  
            
10 I feel resentful that I have to take my medication                                        
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Scale 2 - Self-Monitoring Scale 
 
If you do not monitore, skip the block of questions 
 
 
Please place one tick against each comment to indicate how much you agree or disagree with 
the statement in relation to self-monitoring your blood glucose levels.  
 
          Strongly                          Strongly 
      Agree      Agree  Neutral  Disagree   Disagree 
 
1  I find it especially hard to test when I’m busy                                   
   
2  Self-monitoring makes me feel frustrated                                    
 
3  Self-monitoring makes me fearful of a high                                   
    reading 
4  I don’t feel that self-monitoring is helping me to                                   
    control my diabetes 
 
5  I find it too uncomfortable to self-monitor                                    
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 Scale 3 Knowledge and Beliefs Scale 
 
 
 
Please place one tick against each comment to indicate how much you agree or disagree with 
the statement in relation to your experiences of accessing knowledge about diabetes.  
 
 Strongly                                                    Strongly  
    Agree      Agree         Neutral  Disagree   Disagree 
       
 
1  I do not know as much as I need to know to manage                                
    my diabetes        
 
2  I have difficulty accessing information that is relevant                                  
    to me personally         
 
3  I have difficulty understanding the information from                                
    literature            
 
4  I have difficulty understanding the information from                                     
    health care professionals 
 
5  I think that the information on diabetes is not                                  
   consistent 
 
6  I do not know as much as I need to know about the                                    
    consequences of having diabetes 
 
7  I do not know enough about the treatment for diabetes                                     
 
8 I believe type 2 diabetes is mild compared with type 1                                
 
9  I do not know enough about the benefits of diabetes                                   
    treatment for me personally 
 
10 I don’t believe the consequences of type 2 diabetes                                
     are serious            
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Scale 4 –Diagnosis Scale 
 
 
 
Please place one tick against each comment to indicate how much you agree or disagree with 
the statement in relation to when you were first diagnosed with diabetes.  
 
 
  Strongly              Strongly 
             Agree      Agree   Neutral Disagree  Disagree    
 
1  The way that I was told that I had diabetes made                                 
    me feel confused     
 
2  The way that I was told that I had diabetes made                                 
    me feel afraid      
 
3  The way that I was told that I had diabetes made                                  
    me feel that it was not a serious condition         
 
4  The way that I was told that I had diabetes did not                                
    motivate me to manage my diabetes well         
  
5  I was not given as much information as I needed                                    
    about the consequences of having diabetes 
 
6  The way that I was told that I had diabetes made me                                      
    feel guilty 
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Scale 5 - Relationships with Health Care Professionals Scale 
 
Please place one tick against each comment to indicate how much you agree or disagree with 
the statement about your relationship with healt care professionals. 
 
 
                Strongly                      Strongly 
                       Agree    Agree  Neutral Disagree  Disagree    
 
 
1  I feel my questions about diabetes are not answered                                
     
2  I feel I am not listened to                                    
      
3  I feel my judgment is not trusted in managing my                                 
    diabetes     
4  I am not advised at all on what to do about my                                 
    diabetes    
5  I am not assisted in setting realistic targets for                                 
    changing my lifestyle     
6  Treatment alternatives are not explained to me                                 
        
7  I have not been told what to expect from my                                 
    diabetes    
8  I have not been told what to expect from my                                 
    treatment    
9  I do not feel I am part of the group who                                  
   caring my diabetes    
10  The good and bad aspects of each choice have                                 
    not been discussed with me   
11  I am not asked at all which choice consearning                                  
  my diabetes I would prefer 
12  Talking about my diabetes with group who                                  
    caring my diabetes does not make me feel better   
13  Adjustments to my diabetes plan cannot be discussed                                
    
14  I feel threatened when I go for a checkup                                 
    
15  I feel a sense of helpless when consulting                                 
    with nurses   
16  I feel a sense of helpless when consulting                                 
    with doctors   
17  Times for check visits are inconvenient for me                                 
    
18  I have to spend too much time waiting in clinics                                 
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Scale 6 - Lifestyle Changes Scale 
 
 
 
Please place one tick against each comment to indicate how much you agree or disagree with 
the statement in relation to changes in your lifestyle.  
 
                  Strongly                         Strongly 
                    Agree      Agree  Neutral  Disagree  Disagree    
 
 
 
 
1  My diabetic diet spoils my social life                                  
        
2  I generally still feel hungry after finishing a meal                                   
 
3  My diabetes has placed a strain on my personal                                  
    relationships            
 
4  There is little hope of leading a normal life when you                                 
    have diabetes         
 
5  Changes in my diet have put a strain on my family                                     
 
6  I have difficulty sticking to my diet when I am away                                     
    from home 
 
7  I feel resentful that I am obliged to change my eating                                     
    habits 
 
8 I am unable to fit exercise into my lifestyle                                 
     
9 I am unable to afford the cost of exercising on a                                       
     regular basis 
 
10 I haven’t found an exercise I enjoy                                       
 
11 I lack the motivation to exercise                                    
 
12  Weight control is real problem for me                                       
     
13  I am able to change my lifestyle in accordance with                                    
     advice from health care professional(s) 
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Scale 7 - Coping with Diabetes Scale 
 
 
 
Please place one tick against each comment to indicate how much you agree or disagree with 
the statement in relation to problems with sticking to your diabetes treatment plan. 
 
  
 
                Strongly                            Strongly 
                    Agree      Agree  Neutral Disagree  Disagree      
 
 
 
1  Self management of diabetes is difficult to maintain                                
   because diabetes complications are not immediate 
        
2  Good control of diabetes involves a lot of sacrifice                                
 
3  I find it difficult to get into a suitable routine to cope                                     
    with my treatment plan 
 
4  I am not convinced that the treatment I receive for my                                      
    diabetes is effective 
 
5  I feel overwhelmed by the responsibility of having to                                      
    take my medication 
 
6  I feel that I would like to take a holiday from my                                    
    diabetes 
7  I feel that my family would like to take a holiday                                    
    from my diabetes  
8 I eat something I should not rather than say I have                                      
    diabetes 
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Scale 8 - Advice and Support Scale  
 
 
Please place one tick against each comment to indicate how much you agree or disagree with 
the statement in relation to receiving advice and support about your diabetes. 
 
  
 
                Strongly                        Strongly 
                    Agree      Agree  Neutral Disagree  Disagree    
 
       
 
 
1  I am not convinced health care professionals believe                                 
    the treatment I receive will work for my diabetes  
 
2  I am told too often what I should and should not be                                
   doing to manage my diabetes 
 
3  Constantly repeating what I should be doing to                                  
    manage my diabetes makes me do it less  
 
4  I am criticized too often about the way I manage my                                     
    diabetes 
 
5  I would manage my diabetes much better if I had                                   
    more encouragement socially 
 
6  I feel very alone with my diabetes                                       
     
7  I feel I get little support from my family                                     
     
8  I feel I get little support from my friends                                     
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Appendix B 
 
    Problem Areas In Diabetes (PAID) Questionnaire 
 
INSTRUCTIONS: Which of the following diabetes issues are currently a problem for you?  
Circle the number that gives the best answer for you. Please provide an answer for each 
question.  
 
Not a 
proble
m 
Minor 
problem 
Moderate 
problem 
Somewhat 
serious 
problem 
Serious 
problem 
   t t t t t 
1. Not having clear and concrete goals for your diabetes care?                     0 ........... 1 ............. 2 ............... 3 ................. 4 
 
2. Feeling discouraged with your diabetes treatment  plan?                          0 ........... 1 ............. 2 ............... 3 ................. 4 
 
3. Feeling scared when you think about living with diabetes?                       0 ........... 1 ............. 2 ............... 3 ................. 4 
 
4. Uncomfortable social situations related to your diabetes care                  0 ............ 1 ............. 2 ............... 3 ................. 4 
    (e.g., people telling you what to eat)? 
 
5. Feelings of deprivation regarding food and meals?                                    0 ........... 1 ............. 2 ............... 3 ................. 4 
 
6. Feeling depressed when you think about living with diabetes?                 0 ........... 1 ............. 2 ............... 3 ................. 4 
 
7. Not knowing if your mood or feelings are related to your diabetes?        0 ............ 1 ............. 2 ............... 3 ................. 4 
 
8. Feeling overwhelmed by your diabetes?                                                      0 ............ 1 ............. 2 ............... 3 ................. 4 
 
9. Worrying about low blood sugar reactions?                                               0 ............ 1 ............. 2 ............... 3 ................. 4 
 
10. Feeling angry when you think about living with diabetes?                     0 ............ 1 ............. 2 ............... 3 ................. 4 
 
11. Feeling constantly concerned about food and eating?                             0 ............ 1 ............. 2 ............... 3 ................. 4 
 
12. Worrying about the future and the possibility of serious                        0 ............ 1 ............. 2 ............... 3 ................. 4 
      complications?  
 
13. Feelings of guilt or anxiety when you get off track with your                 0 ............ 1 ............. 2 ............... 3 ................. 4 
      diabetes management?  
 
14. Not "accepting" your diabetes?                                                                 0 ............ 1 ............. 2 ............... 3 ................. 4 
 
15. Feeling unsatisfied with your diabetes physician?                                   0 ............ 1 ............. 2 ............... 3 ................. 4 
 
16. Feeling that diabetes is taking up too much of your   
      mental and physical energy every day?                                                     0 ............ 1 ............. 2 ............... 3 ................. 4 
 
17. Feeling alone with your diabetes?                                                              0 ............ 1 ............. 2 ............... 3 ................. 4 
 
18. Feeling that your friends and family are not supportive of  
      your diabetes management efforts?                                                           0 ............ 1 ............. 2 ............... 3 ................. 4 
 
19. Coping with complications of diabetes?                                                    0 ............ 1 ............. 2 ............... 3 ................. 4 
 
20. Feeling "burned out" by the constant effort needed to  
      manage diabetes?                                                                                         0 ............ 1 ............. 2 ............... 3 ................. 4 
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Käesolevaga kinnitan, et olen korrektselt viidanud kõigile oma töös kasutatud teiste 
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